The United States of America, As Represented by the Secretary, Department of Health and Human Services

Bruce J Baum

Brian Christopher O'Connell

Changyu Zheng

Niamh X Cawley

Yoke Peng Loh

Christopher R Snell

David J Mooney

Kenneth M Yamada

Edna Cukierman

The invention provides a nucleic acid molecule encoding a growth hormone (GH) in which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides a nucleic acid molecule encoding a GH in which the three-dimensional conformation of the RSP sorting signal has been altered such that the GH can be constitutively secreted by the NRSP in a mammalian cell.

Nucleic acids encoding growth hormone with a modified RSP sorting signal

An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5' retroviral LTR nucleic acid sequence, a 3&#x2032; retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5&#x2032; LTR or the 3&#x2032; LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5&#x2032; LTR and the 3&#x2032; LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5&#x2032; and a 3&#x2032; retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.

Hybrid adeno-retroviral vector for the transfection of cells

The invention provides a growth hormone (GH) in which amino acids within the regulated secretory pathway (RSP) sorting signal have been mutated as well as a GH in which the three-dimensional conformation of the RSP sorting signal has been altered, and a composition comprising an effective amount of such a GH in an excipient.

Modified growth hormone

An adenoviral vector is disclosed that includes two adenoviral ITRs, wherein the two adenoviral ITRs flank a packaging signal and a single retroviral LTR operably linked to a nucleic acid sequence of interest, wherein the adenoviral vector does not include a nucleic acid sequence encoding the retroviral structural proteins and wherein the adenoviral vector does not include a second retroviral LTR. In one embodiment, a method for transforming a cell is disclosed. In another embodiment, a method is disclosed for introducing a transgene into a cell with a single viral vector. In a further embodiment, a method is provided for preventing or treating disorder in a subject. A pharmaceutical composition is also provided.

Hybrid adenoviral vector

The present invention generally relates to the field of oral prosthetics and tissue engineering. More specifically, a novel, artificial fluid secreting prosthesis for non-invasive insertion is disclosed. Further, methods of use of the foregoing are provided.

Growing community of inventors

Bethesda, MD, United States of America

Bruce J Baum